Squarepoint Ops LLC Has $2.17 Million Holdings in AMAG Pharmaceuticals, Inc. (AMAG)

Squarepoint Ops LLC lifted its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 548.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 142,566 shares of the specialty pharmaceutical company’s stock after acquiring an additional 120,568 shares during the quarter. Squarepoint Ops LLC owned 0.41% of AMAG Pharmaceuticals worth $2,166,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Two Sigma Advisers LP lifted its stake in AMAG Pharmaceuticals by 126.2% during the 4th quarter. Two Sigma Advisers LP now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $419,000 after acquiring an additional 15,400 shares during the period. Two Sigma Investments LP increased its holdings in AMAG Pharmaceuticals by 129.3% in the 4th quarter. Two Sigma Investments LP now owns 250,589 shares of the specialty pharmaceutical company’s stock worth $3,806,000 after acquiring an additional 141,286 shares in the last quarter. Principal Financial Group Inc. increased its holdings in AMAG Pharmaceuticals by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock worth $4,334,000 after acquiring an additional 1,613 shares in the last quarter. Convergence Investment Partners LLC purchased a new stake in AMAG Pharmaceuticals in the 4th quarter worth approximately $280,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in AMAG Pharmaceuticals by 8.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 697,652 shares of the specialty pharmaceutical company’s stock worth $10,597,000 after acquiring an additional 56,122 shares in the last quarter.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. SunTrust Banks started coverage on shares of AMAG Pharmaceuticals in a report on Tuesday, March 19th. They set a “hold” rating for the company. Cantor Fitzgerald reaffirmed a “hold” rating and set a $14.00 price objective (down from $17.00) on shares of AMAG Pharmaceuticals in a report on Thursday, March 14th. BidaskClub lowered shares of AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 7th. Finally, ValuEngine lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $20.21.

AMAG traded down $0.08 during trading on Friday, reaching $11.83. The company had a trading volume of 818,340 shares, compared to its average volume of 472,028. The company has a market cap of $399.23 million, a PE ratio of -3.05 and a beta of 0.42. AMAG Pharmaceuticals, Inc. has a 52 week low of $10.70 and a 52 week high of $26.10. The company has a quick ratio of 3.01, a current ratio of 3.17 and a debt-to-equity ratio of 0.35.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.38. AMAG Pharmaceuticals had a negative return on equity of 17.10% and a negative net margin of 13.07%. The business had revenue of $88.10 million during the quarter, compared to the consensus estimate of $95.21 million. During the same period last year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was down 31.4% compared to the same quarter last year. As a group, research analysts anticipate that AMAG Pharmaceuticals, Inc. will post -3.2 earnings per share for the current fiscal year.

WARNING: This story was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/squarepoint-ops-llc-has-2-17-million-position-in-amag-pharmaceuticals-inc-amag.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Article: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.